Fusing generative AI with experimental data to create the enzymes of tomorrow.
AI pioneer driving the largest ever IPO for a European Biotech, EXAI. Research driven but commercially focused, Andrew has developed methods that underpin modern drug discovery from drugability to delivering the World’s First AI designed drug to the clinic.
An expert in combining protein structure/function with Gen-AI drug design, Adrian pioneered the design of low molecular weight molecules, culminating in the first AI-designed immuno-oncology molecule to enter clinical trials.
As former Head of Research Innovation at IBM UKI Ed led programs for UK Gov. in AI, HPC & Quantum computering. Cross discipline expertise has led to AI and ML applications effective across materials science and the life sciences.
With expertise covering both biology, chemistry and AI computing, Doug has developed unrivalled cross-disciplinary knowledge, intelligently combining protein and small molecule data with activity and stability information whilst applying machine learning to extract novel insights.
Wanting to join our team and address some of the most pressing global challenges?
We are looking for dedicated researchers who are excited to tackle some of the most important research challenges of our time.